噬菌体市场规模、份额和成长分析（按产品类型、给药途径、分销管道、应用、最终用途产业和地区划分）－2026-2033年产业预测

预计到 2024 年，全球噬菌体市场规模将达到 5,243 万美元，到 2025 年将达到 5,542 万美元，到 2033 年将达到 8,635 万美元，预测期（2026-2033 年）的复合年增长率为 5.7%。

全球噬菌体市场正逐渐成为应对抗生素抗药性和细菌感染疾病等紧迫挑战的关键解决方案。噬菌体是一种靶向细菌的天然病毒，是传统抗生素的一种极具前景的替代方案。抗生素抗药性细菌的日益增加推动了人们对噬菌体疗法的兴趣，该疗法以其高度特异性、对不断进化的细菌菌株的适应性以及对有益微生物群影响极小而着称。临床前和临床研究的良好结果也支持其治疗潜力。製药公司、研究机构和监管机构之间的合作正在促进基于噬菌体的治疗方法的开发和核准。由于噬菌体具有精准靶向有害细菌并提供个人化治疗方案的独特能力，预计它们将在未来的抗菌治疗策略中发挥关键作用。

全球噬菌体市场驱动因素

抗生素抗药性病菌感染的日益增加显着增加了对替代治疗策略的需求。噬菌体是一种能够选择性感染并清除特定细菌的病毒，为应对抗生素抗药性细菌和超级细菌的挑战提供了潜在的解决方案。随着传统抗生素疗效的下降，噬菌体市场正蓬勃发展，这主要得益于人们对能够有效应对这些严重健康威胁的创新个人化治疗方法的迫切需求。这种向噬菌体疗法的转变凸显了对抗抗药性病原体的一种变革性方法，并将噬菌体定位为现代医学的关键资源。

抑制全球噬菌体市场

全球噬菌体市场面临许多限制因素，主要源自于噬菌体疗法中涉及活性病毒。这项特性引发了人们对产品安全性的担忧，从而构成了许多监管障碍。为确保噬菌体疗法的安全性和有效性，需要进行广泛的测试和核准程序，这既耗时又昂贵。此外，区域监管的不一致性以及不同的要求进一步加剧了这一局面，可能阻碍市场成长和扩大用户群。这些挑战共同构成了不利于噬菌体疗法在全球发展和推广的环境。

全球噬菌体市场趋势

全球噬菌体市场呈现显着的发展趋势，这主要得益于人们对创新解决方案以对抗抗药性感染疾病的需求日益增长。随着医疗界对传统抗生素限制的认识不断加深，噬菌体疗法已展现出其特异性靶向并清除抗药性细菌的能力，成为极具前景的替代方案。噬菌体研究的进展、分离技术的改进以及成功的治疗效果，进一步激发了人们对该领域的兴趣和投资。此外，患者和医疗服务提供者对噬菌体疗法的潜力在疗效和安全性的认识不断提高，也推动了其被广泛接受，这有望在未来的市场格局中为噬菌体市场带来显着的成长和创新。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 案例研究

全球噬菌体市场规模（按产品类型和复合年增长率划分）（2026-2033 年）

• 噬菌体益生菌
• 噬菌体疗法

全球噬菌体市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

• 口服
• 外用
• 其他的

全球噬菌体市场规模（依通路划分）及复合年增长率（2026-2033 年）

• 零售药房
• 医院药房
• 网路药房

全球噬菌体市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 胃肠病学
• 呼吸道感染疾病治疗
• 皮肤感染疾病治疗
• 伤口预防
• 泌尿系统感染疾病的治疗

全球噬菌体市场规模（按终端应用产业划分）及复合年增长率（2026-2033 年）

• 医院
• 专科诊所
• 居家医疗
• 其他的

全球噬菌体市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Intralytix（United States）
• Proteon Pharmaceuticals（Poland）
• Phagelux（China）
• Micreos（Netherlands）
• Eliava BioPreparations（Georgia）
• Locus Biosciences（United States）
• Pherecydes Pharma（France）
• APS Biocontrol Ltd.（United Kingdom）
• Qingdao Phagepharm Biotech（China）
• Fixed-Phage Limited（United Kingdom）
• Zeptometrix（United States）
• Phage International, Inc.（United States）
• Micromir（Russia）
• Armata Pharmaceuticals, Inc.（United States）
• Nextbiotics（United States）
• InnoPhage, Ltd（Portugal）
• TechnoPhage（Portugal）
• Eligo Bioscience SA（France）
• NPO Microgen（Russia）
• Pharmex Group, LLC（Russia）

结论与建议

Global Bacteriophage Market size was valued at USD 52.43 Million in 2024 and is poised to grow from USD 55.42 Million in 2025 to USD 86.35 Million by 2033, growing at a CAGR of 5.7% during the forecast period (2026-2033).

The global bacteriophage market is emerging as a vital solution to the pressing issue of antibiotic resistance and bacterial infections. Bacteriophages, which are natural viruses targeting bacteria, present a compelling alternative to conventional antibiotics. The increasing prevalence of antibiotic-resistant bacteria has fueled interest in phage therapy, known for its high specificity, adaptability to evolving bacterial strains, and minimal disruption to beneficial microbiota. Promising results from preclinical and clinical research underscore their therapeutic potential. Collaborations among pharmaceutical companies, research entities, and regulatory bodies are enhancing the development and approval of phage-based therapies. With their unique ability to precisely target harmful bacteria and offer customized treatment approaches, bacteriophages are poised to play a critical role in the future of antimicrobial treatment strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Bacteriophage market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Bacteriophage Market Segments Analysis

Global Bacteriophage Market is segmented by Product Type, Route of Administration, Distribution Channel, Application, End-use Industry and region. Based on Product Type, the market is segmented into Phage Probiotics and Phage Therapeutics. Based on Route of Administration, the market is segmented into Oral, Topical and Others. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on Application, the market is segmented into Gastroenterology, Respiratory Infections Treatment, Skin Infection Treatment, Wound Prophylaxis and Urological Infection Treatment. Based on End-use Industry, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Bacteriophage Market

The rising incidence of antibiotic-resistant bacterial infections is significantly boosting the need for alternative treatment strategies. Bacteriophages, which are viruses that selectively infect and eliminate specific bacteria, present a compelling solution for addressing the challenges posed by antibiotic-resistant strains and superbugs. As traditional antibiotics lose their efficacy, the market for bacteriophages is gaining momentum, driven by the urgent demand for innovative and tailored therapeutic options that can effectively tackle these formidable health threats. This shift toward phage therapy highlights a transformative approach in the fight against resistant pathogens, positioning bacteriophages as a crucial resource in modern medicine.

Restraints in the Global Bacteriophage Market

The global bacteriophage market faces significant constraints primarily due to the involvement of live viruses in bacteriophage therapy. This aspect raises various regulatory hurdles stemming from safety concerns surrounding these products. To guarantee both the safety and efficacy of bacteriophage therapies, extensive testing and approval procedures are necessary, which can be both lengthy and financially burdensome. Additionally, regulatory inconsistencies and differing requirements across regions further complicate the situation, potentially obstructing the market's growth and ability to reach broader audiences. These challenges collectively create a less favorable environment for the advancement and acceptance of bacteriophage therapies worldwide.

Market Trends of the Global Bacteriophage Market

The Global Bacteriophage market is witnessing a notable trend driven by the escalating demand for innovative solutions to tackle antibiotic-resistant infections. As the healthcare community increasingly acknowledges the limitations of traditional antibiotics, bacteriophage therapy emerges as a promising alternative, showcasing the ability to specifically target and eliminate resistant bacteria. Advancements in phage research, isolation techniques, and successful therapeutic outcomes are further fueling interest and investment in this field. Additionally, growing awareness among patients and healthcare providers about the potential efficacy and safety of phage therapy is propelling its acceptance, positioning the bacteriophage market for significant growth and innovation in the coming landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Bacteriophage Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Phage Probiotics
• Phage Therapeutics

Global Bacteriophage Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Topical
• Others

Global Bacteriophage Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Global Bacteriophage Market Size by Application & CAGR (2026-2033)

• Market Overview
• Gastroenterology
• Respiratory Infections Treatment
• Skin Infection Treatment
• Wound Prophylaxis
• Urological Infection Treatment

Global Bacteriophage Market Size by End-use Industry & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Bacteriophage Market Size & CAGR (2026-2033)

• North America (Product Type, Route of Administration, Distribution Channel, Application, End-use Industry)
  • US
  • Canada
• Europe (Product Type, Route of Administration, Distribution Channel, Application, End-use Industry)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Route of Administration, Distribution Channel, Application, End-use Industry)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Route of Administration, Distribution Channel, Application, End-use Industry)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Route of Administration, Distribution Channel, Application, End-use Industry)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Intralytix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Proteon Pharmaceuticals (Poland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phagelux (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Micreos (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eliava BioPreparations (Georgia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Locus Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pherecydes Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• APS Biocontrol Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qingdao Phagepharm Biotech (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fixed-Phage Limited (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zeptometrix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phage International, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Micromir (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Armata Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nextbiotics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InnoPhage, Ltd (Portugal)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TechnoPhage (Portugal)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eligo Bioscience SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NPO Microgen (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmex Group, LLC (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations